公开(公告)号：EP3730502B1

公开(公告)日：2024-10-02

申请号：EP18904663.4

申请日：2018-02-08

IPC: C07F15/00 ,  C07F9/6561 ,  B01J31/28

CPC classification number: B01J31/28 ,  C07F9/6561 ,  C07F15/0053

公开(公告)号：EP4422756A1

公开(公告)日：2024-09-04

申请号：EP22809629.3

申请日：2022-10-27

Applicant: GILEAD SCIENCES, INC.

Inventor： BARTLETT, Mark J. ,  CHIN, Gregory F. ,  CLARKE, Michael O. ,  COSMAN ELLIS, Jennifer L. ,  ENSAN, Deeba ,  GOYAL, Bindu ,  HO, Stephen ,  MACKMAN, Richard L. ,  MISH, Michael R. ,  SIEGEL, Dustin S. ,  TAMSHEN, Kyle C. ,  YANG, Hai

IPC: A61P35/00 ,  C07F9/6561

CPC classification number: C07F9/6561 ,  A61P35/00

公开(公告)号：EP4365179A3

公开(公告)日：2024-07-10

申请号：EP24150040.4

申请日：2018-09-25

Applicant: Novartis AG

Inventor： BONAZZI, Simone ,  CONNOLLY, Michael ,  GLASS, David Jonathan ,  MIHALIC, Manuel ,  PATTERSON, Andrew William ,  ROGGO, Silvio ,  SHAVLAKADZE, Tea

IPC: C07F9/32

CPC classification number: C07F9/6561 ,  A61P19/00 ,  A61P3/04 ,  A61P31/10 ,  A61P9/10 ,  A61P11/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P19/10 ,  A61P37/00 ,  A61P25/02 ,  A61P19/02 ,  A61P9/12 ,  A61P3/10 ,  C07D498/18 ,  A61P1/16 ,  A61P13/12 ,  A61P35/00 ,  C07F7/1804

Abstract: The disclosure relates to compounds of formula (I)

and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.

公开(公告)号：EP4387977A1

公开(公告)日：2024-06-26

申请号：EP22789790.7

申请日：2022-08-16

Applicant: GILEAD SCIENCES, INC.

Inventor： CHUN, Byoung-Kwon ,  CLARKE, Michael O. ,  ENSAN, Deeba ,  KALLA, Rao V. ,  MACKMAN, Richard L. ,  MANDA, Jagadeesh N. ,  NADUTHAMBI, Devan ,  SIEGEL, Dustin S.

IPC: C07F9/6561 ,  A61K31/706 ,  A61P31/12 ,  A61K31/215 ,  A61K45/06

CPC classification number: C07F9/6561 ,  A61K31/706 ,  A61K45/06 ,  A61K31/215

公开(公告)号：EP2940024B1

公开(公告)日：2018-12-05

申请号：EP13867029.4

申请日：2013-12-25

Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Inventor： YANG, Yushe ,  GUO, Bin

IPC: C07D498/04 ,  C07D519/00 ,  C07F9/6561 ,  A61K31/5383 ,  A61K31/675 ,  A61P31/04

CPC classification number: C07D498/04 ,  C07D519/00 ,  C07F5/025 ,  C07F7/1872 ,  C07F9/6561

Abstract: Disclosed are a benzoxazine oxazolidinone compound shown by a general formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an application thereof in preparing a drug for treating an infectious disease and in particular, an infectious disease caused by multidrug resistant bacteria.

公开(公告)号：EP3407401A1

公开(公告)日：2018-11-28

申请号：EP17172393.5

申请日：2017-05-23

Applicant: Novaled GmbH

Inventor： Luschtinetz, Regina ,  Schulze, Benjamin

IPC: H01L51/54

CPC classification number: H01L51/0067 ,  C07F9/5728 ,  C07F9/5765 ,  C07F9/6512 ,  C07F9/6521 ,  C07F9/65583 ,  C07F9/65586 ,  C07F9/6561 ,  H01L51/0052 ,  H01L51/50

Abstract: The present invention relates to a compound of formula 1 and an organic electronic device comprising an organic semiconductor layer, wherein at least one organic semiconductor layer comprises a compound of formula 1:

wherein
X is selected from O, S or Se; Ar 1 is selected from unsubstituted or substituted C 2 to C 60 heteroarylene, and wherein the substituted C 2 to C 60 heteroarylene comprises at least about one to about six substituents, wherein the substituent of the substituted C 2 to C 60 heteroarylene are independently selected from C 1 to C 12 alkyl, C 1 to C 12 alkoxy, CN, OH, halogen; n is 1 or 2; L 1 is selected from a single bond, C 1 to C 4 alkyl, substituted or unsubstituted C 6 to C 36 arylene, wherein the substituent of substituted C 6 to C 36 arylene is selected from C 1 to C 12 alkyl, C 6 to C 18 arylene; L 2 is selected from a single bond or C 1 to C 6 alkyl; R 1 , R 2 are independently selected from substituted or unsubstituted C 1 to C 16 alkyl, wherein the substituent of substituted C 1 to C 16 alkyl is selected from C 6 to C 18 arylene or C 2 to C 12 heteroarylene; wherein the compound of formula 1 comprises at least about 4 of C 6 -arylene rings and a molecular mass of at least about 400 g/mol to about 1800 g/mol.

公开(公告)号：EP2651448B1

公开(公告)日：2018-11-28

申请号：EP11813701.7

申请日：2011-12-13

Applicant: QuiaPEG Pharmaceuticals AB

Inventor： KWIATKOWSKI, Marek

IPC: C07F9/09 ,  C08G81/00 ,  C07F9/165 ,  C07F9/24 ,  A61K47/50

CPC classification number: C08G65/48 ,  A61K47/48215 ,  A61K47/60 ,  C07F9/091 ,  C07F9/094 ,  C07F9/1651 ,  C07F9/1653 ,  C07F9/2408 ,  C07F9/2458 ,  C07F9/2475 ,  C07F9/572 ,  C07F9/65515 ,  C07F9/6561 ,  C08G81/00

Abstract: This document relates to functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such functionalized polymers.

公开(公告)号：EP3399984A1

公开(公告)日：2018-11-14

申请号：EP17736459.3

申请日：2017-01-06

Applicant: Arcus Biosciences, Inc.

Inventor： DEBIEN, Laurent, Pierre Paul ,  JAEN, Juan, Carlos ,  KALISIAK, Jaroslaw ,  LAWSON, Kenneth V. ,  LELETI, Manmohan Reddy ,  LINDSEY, Erick, Allen ,  MILES, Dillon Harding ,  NEWCOMB, Eric ,  POWERS, Jay Patrick ,  ROSEN, Brandon Reid ,  SHARIF, Ehesan UI

IPC: A61K31/70 ,  A61K31/7052 ,  A61K31/7076 ,  C07H19/16 ,  C07H19/20 ,  C07H19/207

CPC classification number: C07H19/23 ,  A61K31/70 ,  A61K31/7052 ,  A61K31/7064 ,  A61K31/7076 ,  C07F9/6561 ,  C07F9/65616 ,  C07H19/04 ,  C07H19/14 ,  C07H19/16 ,  C07H19/20 ,  C07H19/207

Abstract: Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

公开(公告)号：EP2809666B1

公开(公告)日：2018-10-10

申请号：EP13742931.2

申请日：2013-01-30

Applicant: The University of Hong Kong

Inventor： YANG, Dan ,  PENG, Tao ,  SHEN, Jiangang ,  CHEN, Xingmiao

IPC: C07D407/02 ,  C09K3/00 ,  B41M5/327 ,  B41M5/20 ,  C07D311/82 ,  C07D311/90 ,  C07D491/052 ,  C07F9/6561 ,  C07D493/10 ,  C07D493/20 ,  C09B11/08 ,  C09B11/24 ,  C09B69/00 ,  G01N31/22 ,  G01N33/84 ,  C07F7/08

CPC classification number: G01N31/227 ,  C07D311/82 ,  C07D311/90 ,  C07D491/052 ,  C07D493/10 ,  C07D493/20 ,  C07F7/0816 ,  C07F7/2208 ,  C07F7/30 ,  C07F9/6561 ,  C09B11/08 ,  C09B11/24 ,  C09B11/245 ,  C09B69/008 ,  G01N33/582 ,  G01N33/84 ,  Y10T436/170769

Abstract: Provided herein are improved fluorogenic compounds and probes that can be used as reagents for measuring, detecting and/or screening peroxynitrite. The fluorogenic compounds of the invention can produce fluorescence colors, such as green, yellow, red, or far-red. Also provided herein are fluorogenic compounds for selectively staining peroxynitrite in the mitochondria of living cells. Provided also herein are methods that can be used to measure, directly or indirectly, the presence and/or amount of peroxynitrite in chemical samples and biological samples such as cells and tissues in living organisms. Also provided are high-throughput screening methods for detecting or screening peroxynitrite or compounds that can increase or decrease the level of peroxynitrite in chemical and biological samples.

公开(公告)号：EP2922818B1

公开(公告)日：2018-09-05

申请号：EP12888899.7

申请日：2012-11-24

Applicant: Hangzhou Dac Biotech Co., Ltd

Inventor： ZHAO, R. Yongxin

IPC: C07C317/02 ,  C07C317/06 ,  C07F9/30 ,  A61K31/10 ,  A61K31/662 ,  A61K49/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61K31/454 ,  C07F9/572 ,  C07F9/58 ,  C07F9/6558 ,  C07F9/6561 ,  C07D401/12 ,  C07D207/46 ,  C07F9/32 ,  A61K47/68

CPC classification number: C07F9/572 ,  A61K31/10 ,  A61K31/454 ,  A61K31/662 ,  A61K47/6889 ,  C07D207/46 ,  C07D401/12 ,  C07F9/301 ,  C07F9/302 ,  C07F9/3235 ,  C07F9/58 ,  C07F9/65583 ,  C07F9/6561 ,  Y02A50/402 ,  Y02A50/409 ,  Y02A50/415 ,  Y02A50/463 ,  Y02A50/469 ,  Y02A50/48

Abstract: Cell binding agent-drug conjugates comprising hydrophilic linkers, and methods of using such linkers and conjugates are provided.